EDEN
PRAIRIE, Minn., Nov. 21,
2022 /PRNewswire/ -- NeuroOne Medical Technologies
Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical
technology company focused on improving surgical care options and
outcomes for patients suffering from neurological disorders,
announces an appearance by Chief Executive Officer Dave Rosa on Fox Business Network's Mornings
with Maria earlier today. The segment, which aired live at
8:45 a.m. ET, can be viewed online at
on-air-mornings-with-maria.
In conversation with veteran business journalist and anchor
Maria Bartiromo, Mr. Rosa discussed
NeuroOne's mission in advancing a new era in neuroscience with its
game-changing thin film electrode technology developed in
collaboration with Mayo Clinic. NeuroOne recently announced a
milestone achievement for its Evo® sEEG Electrode, receiving
FDA 510(k) clearance to market the system for temporary (less than
30 day) use. Upcoming business catalysts include the market launch
of the Evo® sEEG diagnostic electrode line* and progress on a new
RF ablation system in development, the Company's first therapeutic
electrode technology.
Mornings with Maria on Fox Business Network
(6-9 AM/ET) is the number one
pre-market business news program in cable. Maria Bartiromo and her guests discuss news
stories -- domestic and international -- and other topics that are
expected to impact the economy and markets that day.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental
stage company committed to providing minimally invasive and
hi-definition solutions for EEG recording, brain stimulation and
ablation solutions for patients suffering from epilepsy,
Parkinson's disease, dystonia, essential tremors, chronic pain due
to failed back surgeries and other related neurological disorders
that may improve patient outcomes and reduce procedural costs. For
more information, visit www.n1mtc.com.
Forward Looking Statements
This press release may include forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Except for statements of historical fact, any information
contained in this presentation may be a forward–looking statement
that reflects NeuroOne's current views about future events and are
subject to known and unknown risks, uncertainties and other factors
that may cause our actual results, levels of activity, performance
or achievements to be materially different from the information
expressed or implied by these forward-looking statements. In some
cases, you can identify forward–looking statements by the words or
phrases "may," "might," "will," "could," "would," "should,"
"expect," "intend," "plan," "objective," "anticipate," "believe,"
"estimate," "predict," "project," "potential," "target," "seek,"
"contemplate," "continue, "focused on," "committed to" and
"ongoing," or the negative of these terms, or other comparable
terminology intended to identify statements about the future.
Forward–looking statements may include statements regarding our
market launch of the Evo sEEG diagnostic electrode line and
progress on a new RF ablation system in development. Although
NeuroOne believes that we have a reasonable basis for each
forward-looking statement, we caution you that these statements are
based on a combination of facts and factors currently known by us
and our expectations of the future, about which we cannot be
certain. Our actual future results may be materially different from
what we expect due to factors largely outside our control,
including risks that the partnership with Zimmer Biomet may not
facilitate the commercialization or market acceptance of our
technology; risks that our sEEG electrodes may not be ready for
commercialization in a timely manner or at all, whether due to
supply chain disruptions, labor shortages, the impact of COVID-19
or otherwise; risks that our technology will not perform as
expected based on results of our pre-clinical and clinical trials;
risks related to uncertainties associated with the Company's
capital requirements to achieve its business objectives and ability
to raise additional funds; the risk that the COVID-19 pandemic will
continue to adversely impact our business; the risk that we may not
be able to secure or retain coverage or adequate reimbursement for
our technology; uncertainties inherent in the development process
of our technology; risks related to changes in regulatory
requirements or decisions of regulatory authorities; that we may
not have accurately estimated the size and growth potential of the
markets for our technology; risks relate to clinical trial patient
enrollment and the results of clinical trials; that we may be
unable to protect our intellectual property rights; and other
risks, uncertainties and assumptions, including those described
under the heading "Risk Factors" in our filings with the Securities
and Exchange Commission. These forward–looking statements speak
only as of the date of this press release and NeuroOne undertakes
no obligation to revise or update any forward–looking statements
for any reason, even if new information becomes available in the
future.
* Caution: Federal law restricts this device to sale by or on
the order of a physician.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neuroone-ceo-dave-rosa-featured-on-fox-business-networks-mornings-with-maria-301684003.html
SOURCE NeuroOne Medical Technologies Corporation